489 related articles for article (PubMed ID: 29120755)
1. Migrating into the Tumor: a Roadmap for T Cells.
van der Woude LL; Gorris MAJ; Halilovic A; Figdor CG; de Vries IJM
Trends Cancer; 2017 Nov; 3(11):797-808. PubMed ID: 29120755
[TBL] [Abstract][Full Text] [Related]
2. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
4. Enhancing tumor T cell infiltration to enable cancer immunotherapy.
Zhang J; Endres S; Kobold S
Immunotherapy; 2019 Feb; 11(3):201-213. PubMed ID: 30730277
[TBL] [Abstract][Full Text] [Related]
5. Regulation of CTL Infiltration Within the Tumor Microenvironment.
Church SE; Galon J
Adv Exp Med Biol; 2017; 1036():33-49. PubMed ID: 29275463
[TBL] [Abstract][Full Text] [Related]
6. Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment.
Nguyen HH; Kim T; Song SY; Park S; Cho HH; Jung SH; Ahn JS; Kim HJ; Lee JJ; Kim HO; Cho JH; Yang DH
Sci Rep; 2016 Jun; 6():28208. PubMed ID: 27306834
[TBL] [Abstract][Full Text] [Related]
7. Improving homing in T cell therapy.
Vignali D; Kallikourdis M
Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108
[TBL] [Abstract][Full Text] [Related]
8. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Barriers to T Cell Function in Tumors.
Sugiura A; Rathmell JC
J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
[TBL] [Abstract][Full Text] [Related]
10. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.
Capitani N; Patrussi L; Baldari CT
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681881
[TBL] [Abstract][Full Text] [Related]
11. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
Scarfò I; Maus MV
J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
[TBL] [Abstract][Full Text] [Related]
12. Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.
Di Caro G; Castino GF; Bergomas F; Cortese N; Chiriva-Internati M; Grizzi F; Mantovani A; Marchesi F
Int Rev Immunol; 2015 Mar; 34(2):123-33. PubMed ID: 25901857
[TBL] [Abstract][Full Text] [Related]
13. Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.
Rangel Rivera GO; Knochelmann HM; Dwyer CJ; Smith AS; Wyatt MM; Rivera-Reyes AM; Thaxton JE; Paulos CM
Front Immunol; 2021; 12():645242. PubMed ID: 33815400
[TBL] [Abstract][Full Text] [Related]
14. NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
Simon PS; Bardhan K; Chen MR; Paschall AV; Lu C; Bollag RJ; Kong FC; Jin J; Kong FM; Waller JL; Pollock RE; Liu K
Oncotarget; 2016 Apr; 7(17):23395-415. PubMed ID: 27014915
[TBL] [Abstract][Full Text] [Related]
15. Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms.
Davoodzadeh Gholami M; Kardar GA; Saeedi Y; Heydari S; Garssen J; Falak R
Cell Immunol; 2017 Dec; 322():1-14. PubMed ID: 29079339
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment.
Weigelin B; Krause M; Friedl P
Immunol Lett; 2011 Jul; 138(1):19-21. PubMed ID: 21333682
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
18. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
Olson DJ; Luke JJ
Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
[No Abstract] [Full Text] [Related]
19. Dormant tumour cells, their niches and the influence of immunity.
Goddard ET; Bozic I; Riddell SR; Ghajar CM
Nat Cell Biol; 2018 Nov; 20(11):1240-1249. PubMed ID: 30361702
[TBL] [Abstract][Full Text] [Related]
20. Trafficking of T cells into tumors.
Slaney CY; Kershaw MH; Darcy PK
Cancer Res; 2014 Dec; 74(24):7168-74. PubMed ID: 25477332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
